Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy

N/ACompletedNCT05197504

CHA University166 enrolled

Overview

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide, and HCC is more frequently observed in Asia, including South Korea. As HCC is often accompanied by chronic hepatitis B or C virus and liver cirrhosis, treatment of HCC consider not only the tumor but also various factors such as liver function and the patient's performance status. Local treatment and surgery are possible in the early stages of HCC. However, it has a high recurrence rate even after curative surgeries due to underlying cirrhosis and the tumor microenvironment. Although several studies have investigated gene mutations and differences in treatment response in advanced HCC through next-generation sequencing (NGS), studies on transcriptome analysis of advanced HCC through RNA-sequencing are hard to find, with a need for future research into precise classification and clinical significance of HCC based on multi-omics data.

to establish multi-omics data and discover biomarkers highly associated with treatment response in HCC patients

Study Type

OBSERVATIONAL

Enrollment

166

Conditions

Hepatocellular Carcinoma

Interventions

atezolizumab plus bevacizumab

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Those above the age of 20 who understand the purpose of the study and agree to participate in the collection of samples during the study. * Patients who have been diagnosed with unresectable advanced HCC through imaging, histological, or cytological tests. * Patients who underwent an NGS test with advanced HCC tissues * Patients who are scheduled to receive systemic treatment * Patients with measurable lesions based on RECIST v1.1 * ECOG performance status 0 or 1 * Patients with a life expectancy of at least three months Exclusion Criteria: * Patients who have systemic conditions accompanied by instability of vital signs, such as infections or organ failure * Those with mental/neurological conditions or dementia who have difficulties understanding and completing the consent form * Those who are assessed as not suitable for this study, at the discretion of the researcher

Outcomes

Primary Outcomes

collected tumor samples

tumor samples from patients with hepatobiliary cancers (incidence of genetic alteration, association with treatment response and survival duration)

Time frame: through study completion, an average of 3 years

collected blood samples

blood samples from patients with hepatobiliary cancers (incidence of genetic alteration, association with treatment response and survival duration)

Time frame: through study completion, an average of 3 years

Secondary Outcomes

Multi-omics analysis

Multi-omics analysis to further subtype and find therapeutic targets of HCC

Time frame: 3 years

Biomarkers on the efficacy of Atezolizumab+Bevacizumab for advanced HCC

Molecular biomarker associated with overall survival, progression-free survival and objective response rate in patients who receive atezolizumab plus bevacizumab